LifeScan has launched the OneTouch® Verio®IQ system, which is designed to identify patterns of high or low blood glucose, enabling patients and healthcare professionals to take early corrective action, and potentially helping reduce diabetes-associated complications. The strip features Verio® PatternAlertTM technology, which alerts patients to only the most relevant blood glucose patterns.
Jentadueto®: CHMP recommend approval
The Committee for Medicinal Products for Human Use (CHMP) has recommended European approval of Jentadueto® for use with diet and exercise to improve glycaemic control in patients with type 2 diabetes.
Combining the dipeptidyl peptidase-4 inhibitor linagliptin and metformin in a single tablet, Jentadueto® could provide an alternative treatment option for patients who have not achieved adequate control of their blood glucose with metformin alone or in combination with linagliptin.
Fixed combinations may increase patient adherence to treatment and “are to be welcomed” says Tony Barnett, Professor of Medicine, University of Birmingham, UK.
Novo Nordisk FlexTouch®
The FlexTouch® disposable insulin pen has been ranked better than the InnoLet® doser with respect to injection and handling procedure in patients with poor eyesight or manual dexterity.
The study (n=90) by the Institute for Clinical Research and Development (IKFE; Mainz, Germany) reported 92% of patients recommended FlexTouch® over InnoLet®.
Gwen Hall, Diabetes Specialist Nurse and Vice Chair of the Primary Care Diabetes Society, said: “This study confirms that this … innovative device gives [people] more choice to effectively manage their diabetes.”
The study findings were presented at the 2012 Diabetes UK Professional Conference.
Attempts to achieve remission, or at least a substantial improvement in glycaemic control, should be the initial focus at type 2 diabetes diagnosis.
9 May 2024